Vice President and Head of US Medical Affairs
Otonomy is a biotech and biopharmaceuticals company developing ear medicine and therapeutics to address unmet medical needs in the emerging otology market.
Dean Hakanson M.D. Chief Medical Officer Otonomy, Inc DHakanson@otonomy.com About Otonomy Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic injection. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery, and a New Drug Application for AuriPro in this indication has been submitted to the FDA. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Ménière's disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information please visit www.otonomy.com. Specialties: Product Development, Managed Markets and Medical Affairs - Managed Markets Account Management - Contract negotiations and Sales - Health Economic and Outcome Research - KOL development - Publication strategy and medical communications.
Anymail finder is trusted by tens of thousands of companies to provide accurate contact information to their Sales and Business Development teams.
If you're looking to find the email of Dean Hakanson Md at Otonomy then you've come to the right place.
Wondering if it's dean@otonomy.com, dean.md@otonomy.com, md@otonomy.com, or dmd@otonomy.com? We have the answers for you.